Combined protein and transcriptomics identifies DCTPP1 as a putative biomarkers for predicting immunotherapy responsiveness in gastric cancer patients

被引:0
|
作者
Wei, Jun [1 ,2 ]
Qin, Yuexuan [3 ]
Zhang, Luwen [4 ]
Gong, Xiaobing [1 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Gastroenterol, Gen Practice, 613 Huangpu Ave West, Guangzhou 510630, Guangdong, Peoples R China
[2] Bengbu Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Bengbu, Anhui, Peoples R China
[3] Bengbu Med Univ, Sch Life Sci, Bengbu, Anhui, Peoples R China
[4] Bengbu Med Univ, Sch Clin Med, Bengbu, Anhui, Peoples R China
关键词
biomarker; DCTPP1; gastric cancer; immunotherapy; prognosis; CELLS;
D O I
10.1097/CAD.0000000000001704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to screen the changes after overexpression of dCTP pyrophosphatase 1 (DCTPP1) in human gastric adenocarcinoma cells (AGS) cells by proteome and transcriptome sequencing. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were performed to explore the functional significance of the differentially expressed DCTPP1 in gastric cancer (GC). Cell Counting Kit-8 (CCK-8) assay was used to detect the proliferation of cells. Western blot was used to detect the expression of proteins. A total of 28 genes that were significantly associated with DCTPP1 overexpression and had prognostic value were screened by Cox regression analysis. The results of gene set enrichment analysis showed that the genomes of patients with subtype A exhibited significant enrichment in pathways such as DNA repair, pyrimidine synthesis, and glucose metabolism. The tumor immune dysfunction and exclusion and The Cancer Immunome Atlas databases showed that patients with type A GC were better candidates for immunotherapy than patients with type B GC. Furthermore, the CCK-8 assay indicated significantly enhanced proliferative activity after overexpressing DCTPP1 in AGS cells, corroborating the findings from the bioinformatic analysis. The data suggest a potential association between DCTPP1 expression and both the prognosis of GC patients and the efficacy of immunotherapy. These findings offer valuable insights for the potential optimization of therapeutic strategies in gastric cancer.
引用
收藏
页码:415 / 426
页数:12
相关论文
共 4 条
  • [1] Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients
    Sun, Jiangang
    Li, Xiaojing
    Wang, Qian
    Chen, Peng
    Zhao, Longfei
    Gao, Yongshun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [2] A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer
    Zhang, Daoming
    Li, Yuan
    Li, Haoyue
    Tang, Tian
    Zheng, Yongfa
    Guo, Xufeng
    Xu, Ximing
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7131 - 7137
  • [3] A nomogram for predicting survival based on hemoglobin A1c and circulating tumor cells in advanced gastric cancer patients receiving immunotherapy
    Wei, Chenyu
    Sun, Haolin
    Liu, Shujing
    Hu, Jiexuan
    Cao, Bangwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
  • [4] Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial
    Tandaric, Luka
    Auranen, Annika
    Kleinmanns, Katrin
    DePont Christensen, Rene
    Vestrheim Thomsen, Liv Cecilie
    Wogsland, Cara Ellen
    Mccormack, Emmet
    Maenpaa, Johanna
    Madsen, Kristine
    Stampe Petersson, Karen
    Mirza, Mansoor Raza
    Bjorge, Line
    MOLECULAR ONCOLOGY, 2025,